1. Scrip
  2. >>New Products

Neurocrine’s Ingrezza Adds Huntington’s Indication, May Have Competitive Edge

Extended-Release Rival Also Approved In 2023

 
• By Mandy Jackson

The company’s VMAT2 inhibitor joins others in the drug class with a warning about suicidal ideation, but its once-daily dosing without titration may be an advantage in chorea associated with Huntington’s disease.

Leadership concept, One leader red sphere leads other boxes
Ingrezza sales already outpace Austedo • Source: Shutterstock

Neurocrine Biosciences, Inc.’s Ingrezza (valbenazine) won its second indication in the US with approval to treat chorea associated with Huntington’s disease (HD), six years after its Food and Drug Administration approval for tardive dyskinesia. Rival VMAT2 inhibitor Austedo (deutetrabenazine) from Teva Pharmaceutical Industries Ltd. has been approved for both indications since 2017, so Neurocrine’s product is just catching up in the smaller HD chorea market, but it may capitalize on certain competitive advantages.

However, the gap between the two products may be closing in 2023, since Teva won FDA approval in February for Austedo XR, an extended-release version of the original product that is dosed once-daily and does not require patients to take the medicine with food

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from New Products

Pipeline Watch: Six Approvals And Thirteen Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Verastem Wins Approval For Novel Drug Combo In Rare Ovarian Cancer

 
• By Jessica Merrill

The novel RAF/MEK inhibitor and FAK inhibitor are the first treatment approved specifically for KRAS-mutated recurrent low-grade serious ovarian cancer (LGSOC).

Pipeline Watch: Thirteen Approvals And Ten Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

J&J’s Imaavy Approval Is The Starting Line For Pipeline-In-A-Product Strategy

 
• By Jessica Merrill

The company’s FcRn inhibitor nipocalimab was approved by the US FDA for generalized myasthenia gravis (gMG), where it will join a competitive market.

More from Scrip

Finance Watch: Deerfield Closes $600m-Plus VC Fund; Gates Speeds Up Health Investments

 
• By Mandy Jackson

Private Company Edition: Deerfield’s third innovations fund will back therapeutics and other opportunities, the Gates Foundation – a sometimes funder of biotech firms – will spend $200bn over the next 20 years, and NewLimit raised a $130m series B round, among other financings.

Pipeline Watch: Six Approvals And Thirteen Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Pharma Left Hanging After US/UK Trade Pact

 
• By Kevin Grogan

An ‘historic economic prosperity deal’ does not include the sector.